Suzhou Degen Biopharmaceutical

Suzhou Degen Biopharmaceutical is a clinical-stage biotechnology company headquartered in the Suzhou Industrial Park, China. The company is dedicated to the discovery and development of innovative small molecule drugs, primarily focusing on metabolic diseases and oncology. Its lead candidate, DG-001, is a highly selective thyroid hormone receptor beta (THRβ) agonist currently being evaluated for the treatment of non-alcoholic steatohepatitis (NASH). Degen Biopharmaceutical aims to address significant unmet medical needs through its robust internal research and development platform. The leadership team consists of industry veterans with extensive experience in global pharmaceutical companies.